OBJECTIVES: To characterize pelvic floor and urinary symptoms in a cohort of women presenting for evaluation and treatment of uterine fibroids. MATERIALS AND METHODS: Premenopausal English-speaking women seeking treatment for uterine fibroids at a single academic medical center were enrolled in this cross-sectional study. Participants completed the Symptom Severity subscale of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) and the Pelvic Floor Distress Inventory . The Symptom Severity subscale of the UFS-QOL is composed of 8 items, whereas the PFDI-20 contains 20 items with 3 subscales: the Pelvic Organ Prolapse Distress Inventory (POPDI-6), Colorectal-Anal Distress Inventory (CRADI-8), and the Urinary Distress Inventory (UDI-6). Scores on both the Symptom Severity subscale of the UFS-QOL and the PFDI-20 range from 0 to 100, with higher scores indicating greater symptom severity or bother. RESULTS: One hundred ninety-five women with mean age of 41 AE 6 years and BMI of 29 AE 7 kg/m 2 were included in this analysis. Fiftyeight percent identified as black, 32% as white, and 6% as Asian. Median parity was 0 (0-4) with 38% of women having had at least one vaginal delivery. Mean age at fibroid diagnosis was 34 AE 7 years. Women commonly attributed heavy vaginal bleeding (81%), pelvic pain (68%), increased abdominal size (66%), length of menses (56%), dyspareunia (37%), and urinary incontinence (31%) to their fibroids. The mean UFS-QOL Symptom Severity subscale score was 48.7 AE 25.4 for the cohort, with 81% of participants reporting being at least "somewhat bothered" by heavy bleeding during menses, 79% by passing clots, 66% by feeling fatigued, 63% by tightness or pressure in pelvic area, 60% by frequent daytime urination, and 47% by frequent night time urination. Mean PFDI-20 score was 45.5 AE 31.9 for the cohort with mean subscale scores of 17.2 AE 12.2, 9.3 AE 10.7, and 19.0 AE 15.8 for the POPDI-6, CRADI-8, and UDI-6, respectively. Women most commonly reported being at least "somewhat bothered" by pressure in the abdomen (71%), heaviness or dullness in the pelvis (60%), frequent urination (56%), pelvic pain or discomfort (48%), sensation of incomplete bladder emptying (43%), and incomplete emptying at the end of a bowel movement (42%). Fewer women reported bother from stress urinary incontinence (36%), urgency urinary incontinence (35%), and difficulty with bladder emptying (21%). Other pelvic floor symptoms such as vaginal bulge (15%), needing to push on the vagina or around the rectum to complete a bowel movement (12%), and needing to push in the vagina to initiate or complete urination (7%) were uncommon. CONCLUSION: Women presenting for evaluation and treatment of fibroids report high rates of pelvic floor symptom bother, particularly related to urinary frequency and pelvic pressure. Given the observed frequency of pelvic floor symptoms, future studies should assess interventions for pelvic floor dysfunction in this patient population.
cases of ovarian endometriomas. The infiltrative extent of ovarian endometrioma has not been previously defined in the literature. We aimed to identify the histologic forms of ovarian endometriosis and its relations to clinical symptoms of pain and infertility, to the proliferative activity (Ki-67) and to the molecular expression of apoptotic mechanisms (p53 and Bcl-2). MATERIALS AND METHODS: This is a retrospective cohort study including 80 consecutive women who had laparoscopic and histologic confirmation of ovarian endometriosis. The study was approved by the Sao University Medical School Review Board (0525/ 11). The specimens were classified according to the presence of the disease in the surface of the ovaries (superficial disease), in the capsule of the ovarian cyst (cystic ovarian endometriosis) or when the disease infiltrated the ovarian parenchyma (intra-parenchymatous ovarian disease). RESULTS: The most frequent form of ovarian endometriosis was the cystic disease (72.5%), followed by intra-parenchymatous ovarian endometriosis (22.5%) and superficial ovarian endometriosis (5%). No associations were found among symptoms, concomitant disease, markers expression and the histologic types of ovarian endometriosis. CONCLUSION: Ovarian endometriosis has three distinct infiltrative extents as confirmed by histology. Although this pilot study did not show any correlation between infiltrative extent, clinical manifestation and to the markers expression., future studies involving larger sample sizes and other markers should be considered.
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